Navigation Links
U of M researcher examines newly emerging deadly disease

Researchers at the University of Minnesota have identified a newly emerging illness, named staphylococcal purpura fulminans. The disease begins as a respiratory tract infection, which then is infected by Staphylococcus aureus. The infection then moves to the lungs, making superantigens (bacterial toxins that activate large numbers of T cells), often leading to death due to hypertension and shock. Purpura fulminans has been identified in five cases in the Minneapolis-St. Paul, Minn., metropolitan area during 2000-2004, as described in the April 1, 2005 issue of Clinical Infectious Diseases. This new disease has also been determined in seven additional cases nationwide. Of the 12 known cases, only two patients have survived.

Purpura fulminans is an acute illness commonly associated with meningococcemia or invasive streptococcal disease, and it is typically characterized by the depletion of clotting factors in the blood and skin lesions. Purpura fulminans refers to widespread severe purpura with extensive tissue damage and sloughing of skin. Purpura are skin lesions that may be many centimeters in diameter caused by the leakage of blood into the skin.

"It is important to alert medical professionals about the symptoms and treatments of this new deadly disease," said Patrick Schlievert, Ph.D., professor of microbiology at the University of Minnesota Medical School. "We are continuing to study and monitor cases of purpura fulminans to better understand the causes and best treatment options."

On the basis of experience, the University of Minnesota experts have identified three recommended treatments for purpura fulminans. Patients who present symptoms of purpura should receive antibiotic therapy not only against Neisseria meningitidis and streptococci, but also against methicillin-resistant S. aureus (MRSA), with the consideration that the staphylococcal disease may be more common than the two prior illnesses. Patients should also be given early admi nistration of activated protein C (i.e., drotrecogin) in an attempt to minimize purpuric skin injury and to slow the inflammatory cascade before irreparable tissue injury occurs. In addition, because toxic shock syndrome is mediated by superantigens, it is possible that intravenous immunoglobulin therapy may be indicated. Of the five patients observed in the Minneapolis-St. Paul area during the period of 2000-2004, four of the patients were previously healthy and four of the patients were women. Schlievert and colleagues hypothesize that the clinical features of purpura fulminans and toxic shock syndrome seen in these patients resulted from massive cytokine release induced by the S. aureus strains.


'"/>

Source:University of Minnesota


Related biology news :

1. NYU researchers simulate molecular biological clock
2. Vital step in cellular migration described by UCSD medical researchers
3. ASU researchers finds novel chemistry at work to provide parrots vibrant red colors
4. UCSD researchers maintain stem cells without contaminated animal feeder layers
5. Why do insects stop breathing? To avoid damage from too much oxygen, say researchers
6. New protein discovered by Hebrew University researchers
7. First real-time view of developing neurons reveals surprises, say Stanford researchers
8. Agilent Technologies releases automated literature search tool for biology researchers
9. Self-assembled nano-sized probes allow Penn researchers to see tumors through flesh and skin
10. Yale researchers identify molecule for detecting parasitic infection in humans
11. US life expectancy about to decline, researchers say
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/14/2019)... ... 14, 2019 , ... Representatives with MyBioGate announced that China Focus@Biotech Week will ... “We help innovative projects connect with Chinese pharma and investors in healthcare innovation,” said ... to explain that as a part of Biotech Week Boston – the annual biotech ...
(Date:8/14/2019)... ... ... Dr. Julie Reck of Veterinary Medical Center of Fort Mill has recently begun ... patient, her own geriatric Australian Shepherd, Simon, was treated in June 2019 for osteoarthritis in ... his body was weak, and he struggled to play fetch and other games with his ...
(Date:8/6/2019)... ... August 06, 2019 , ... VetStem ... clinical, regulatory and GMP manufacturing experience. In November it spun out a ... extensive regulatory experience and one of the first cGMP cell manufacturing facilities ...
Breaking Biology News(10 mins):
(Date:7/23/2019)... ... July 22, 2019 , ... While ... services in the fields of 3D tissue imaging , digital pathology ... initially started back in 2013 as a products company. These products are focused ...
(Date:7/19/2019)... ... July 18, 2019 , ... World ... will be joining forces with California-based charity Coalition Duchenne for its 9th Annual ... Duchenne raises awareness and funding for Duchenne muscular dystrophy and was founded by ...
(Date:7/17/2019)... N.J. (PRWEB) , ... July ... ... announced a long-term strategic agreement for the development and manufacturing of Zolgensma® ... , Through this collaboration, AveXis, a Novartis company, will have dedicated manufacturing ...
(Date:7/11/2019)... (PRWEB) , ... July 11, 2019 , ... At the ... provided complimentary regenerative therapies to eight military Veterans under the R3 Heroes Program. The ... complimentary. , The R3 Heroes Program allow anyone to nominate a military Veteran, teacher ...
Breaking Biology Technology: